CAPLIPOINT · Caplin Point Laboratories Ltd · Biotechnology & Drugs
CAPLIPOINT · Caplin Point Laboratories Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
19.0% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹610 Cr
Revenue YoY
PAT YoY
+15.8%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
5.6
P/S (TTM)
9.2
Sector P/E
36.3
Dividend yield
+0.3%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| CAPLIPOINT (this stock) | 30 | 5.6 | +29.1% | +18.6% | 0 | +0.3% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
falling 2q
MF
2.03% (+0.01pp)
stable
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
- loweconomictimes.indiatimes.com· 24 Aug 2026, 06:00 amStocks in news: Reliance Industries, Bank of Baroda, Power Grid, NATCO Pharma and JSW Infra
Concalls & investor presentations
AI-generatedKey takeaway: The earnings call transcript for Caplin Point Laboratories Limited, held on August 12, 2026, discussed the company's financial performance for the quarter ending June 30, 2026. The document confirmed that the transcript is available on the company's website, in compliance with SEBI regulations. The communication was signed by Venkatram G, General Counsel & Company Secretary, and included details for record-keeping by BSE and NSE.
The document provided factual information regarding the earnings call and compliance without emphasizing any particular performance aspect.
Sourced from an exchange-filed transcript, dated 19 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: On August 12, 2026, Caplin Point Laboratories Limited's Board of Directors approved several key decisions during their meeting. The unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, were approved, along with a final dividend of Rs. 4 per equity share for the financial year ended March 31, 2026, subject to shareholder approval at the upcoming Annual General Meeting (AGM). The Board also approved the re-appointment of Dr. Sridhar Ganesan as Managing Director for two more years and the appointment of Mr. D. Muralidharan as Whole-Time Director. The 35th AGM is scheduled for September 25, 2026. The financial results indicated a total income of Rs. 643.91 crores for Q1 FY27, reflecting a 20.7% year-on-year increase, with a net profit of Rs. 179.09 crores, an 18.8% increase from the previous year.
Management highlighted strong financial performance and strategic decisions during the meeting.
Sourced from an exchange-filed presentation, dated 12 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: The earnings call transcript for Caplin Point Laboratories Limited, covering the financial performance for Q4 and the year ended March 31, 2026, was made available on the company's website. This communication followed a prior letter dated May 07, 2026, and was issued in compliance with SEBI regulations. The document was signed by Venkatram G, General Counsel & Company Secretary, and includes details pertinent to the company's financial disclosures.
The document provided factual information regarding the earnings call and compliance with regulatory requirements.
Sourced from an exchange-filed transcript, dated 21 May 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: The earnings call transcript for Caplin Point Laboratories Limited, held on February 5, 2026, discussed the company's financial performance for the quarter and nine months ended December 31, 2025. The document confirmed that the transcript is available on the company's website, following a prior communication dated January 29, 2026, in compliance with SEBI regulations. The correspondence was signed by Venkatram G, General Counsel & Company Secretary.
The document provided factual information regarding the earnings call and its availability.
Sourced from an exchange-filed transcript, dated 11 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: On February 5, 2026, Caplin Point Laboratories Limited announced the outcome of its Board meeting, where the Board approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The presentation reported a total revenue of ₹1,674 crores for the nine months, reflecting an 11.2% year-over-year increase, and a profit after tax (PAT) of ₹477 crores, marking a 20.5% increase year-over-year. For Q3 FY26, the total revenue was ₹576 crores, a 9.9% increase year-over-year. The company highlighted strong performance in the US market, with revenue of ₹335 crores, a 25% growth year-over-year. Management emphasized ongoing investments in capacity and technology, with a focus on maintaining strong margins and cash generation. The company also outlined strategic initiatives in emerging markets and the US, including new product approvals and facility expansions.
Management emphasized strong financial performance and strategic growth initiatives.
Sourced from an exchange-filed presentation, dated 05 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedCaplin Point Laboratories Limited's FY2025-26 annual report highlights strategic priorities centered on sustainability, governance, and operational resilience. The company emphasizes ESG integration, with initiatives like a dedicated CSR and Sustainability Committee, management's stated coverage of 100% of employees under a code of conduct, and adherence to multi-jurisdictional regulatory standards. It also outlines risk management frameworks addressing operational, regulatory, geopolitical, and financial risks through diversification, compliance automation, and localized manufacturing. The report underscores a focus on backward and forward integration to strengthen the value chain, including API self-sufficiency and geographic expansion.
- Commitment to ESG with a dedicated CSR and Sustainability Committee and management's stated coverage of 100% of employees under a code of conduct.
- Operational resilience through diversified sourcing, vertical API integration, and localized manufacturing.
- Robust risk management with specialized committees and strategies for regulatory compliance and geopolitical challenges.
- Strategic focus on backward and forward integration to enhance self-sufficiency and market reach.
Key takeaway: Caplin Point Laboratories prioritizes ESG integration, operational resilience, and strategic value chain integration to navigate risks and sustain growth in a complex global pharmaceutical landscape.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Auditor Qualification (1 item); Regulatory Action (1 item); Default / Covenant Breach (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Auditor Qualification
1 occurrenceOlder (3+ years ago)
The auditor identified key audit matters related to the impact of the Covid-19 pandemic on the company's operations and financial statements, which were addressed in the audit procedures.
Regulatory Action
1 occurrenceOlder (3+ years ago)
The company received a notice from NSE dated 8th January 2021 regarding non-compliance of Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for not uploading the Annual Report for the Financial Year ended 31st March 2020 on the NSE website, and a fine was imposed.
Default / Covenant Breach
1 occurrenceEarlier (1-3 years ago)
The company has income tax dues of 13.40 crore under the Income Tax Act, 1961 for assessment years 2013-2014 to 2018-2019, pending in various judicial forums. The courts have ruled in favor of the company, but the Assessing Officer has not yet issued orders to implement these decisions.
Routine disclosures
Internal Control Weakness
1 occurrenceOlder (3+ years ago)
The company has identified a material weakness in its internal controls over financial reporting.
Contingent Liability
6 occurrencesRecent (last 12 months)
The company has disputed statutory dues under the Income Tax Act, 1961 for AY 2018-19, with the dispute pending at CIT (Appeals) as of March 31, 2026.
Earlier (1-3 years ago)
The company has disputed statutory dues under various statutes, which are classified as contingent liabilities not provided for in the financial statements as of March 31, 2025.
The company has disputed statutory dues under the Income Tax Act, 1961, with the dispute pending before the CIT (Appeals) as of March 31, 2024.
Older (3+ years ago)
The company has disputed statutory dues under the Income Tax Act, 1961, with the Dispute Resolution Forum in Chennai as of March 31, 2023.
The company has disputed statutory dues under the Income Tax Act, 1961, amounting to 1.02 DCIT, Chennai, as of March 31, 2022.
The company has disputed statutory dues under the Income Tax Act, 1961, with disputes pending at the Income Tax Appellate Tribunal or CIT Appeals as of March 31, 2021.
Related-Party Transaction
6 occurrencesRecent (last 12 months)
The company transferred ₹1.00 crore to Caplin Point Meenakshi CSR Trust during the year, which is a related party transaction as per the disclosure in the notes to the standalone financial statements.
Earlier (1-3 years ago)
The company paid rent and consultancy charges to Ashvich Infotek Private Limited by Caplin Point Laboratories Limited and Caplin Steriles Limited during the year ended March 31, 2025.
The company transferred ₹3.59 crore to Caplin Point Meenakshi CSR Trust during FY24, which is a related party transaction as per the disclosure in Note 49.
Older (3+ years ago)
The company transferred ₹0.50 Cr to Caplin Point Meenakshi CSR Trust during the year, which is a related party transaction.
The company has disclosed transactions with Ashvich Infotek Private Limited, including rent, consultancy charges, and asset purchases by its subsidiaries Caplin Steriles Ltd and Caplin Point Laboratories Ltd during the year ended March 31, 2022.
The company seeks shareholder approval for a material related party transaction with Caplin Point Laboratories Limited, a step-down subsidiary, involving sales of goods worth Rs. crores for the Financial Year 2021-22.
Statutory dues in dispute
1 occurrenceOlder (3+ years ago)
The company has disputed income tax matters for the assessment years 2008-09, 2014-15, 2015-16, 2017-18, and 2018-19, with disputes pending before the DCIT, Chennai.
Management & Board Governance
1 occurrenceOlder (3+ years ago)
Dr. B. Philip Ashok Karunakaran, a Whole-time Director, resigned on 10.04.2019. Mr. Vinod Kumar S, Company secretary, resigned on 05.02.2021.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
2.53% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).